Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Takeda Pharmaceutical Company Limited ( NYSE: TAK) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Christopher O’Reilly - Head, Investor Relations Christophe Weber - President and Chief ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Management View Christophe Weber, CEO, announced his retirement ...

ADRs traded higher in the premarket on Thursday after the Japanese drugmaker raised its full-year outlook with its Q3 FY24 results and named Julie Kim, head of its U.S. business, as the company’s next ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Mahindra & Mahindra Financial Q3 Results 2025: Profit Rises by 47.39% YOY, Profit at ₹917.57 Crore and Revenue at ₹4796.8 Crore ...

Company has reported net profit after tax of Rs 93.06 Crore in latest quarter.The company’s top management includes Mr.Sanjay Labroo, Mr.Masao Fukami, Mr.Gurvirendra Singh Talwar, Mr.Masahiro Takeda, ...